Loading company…
Riskpilot
← Back to search
Sign in
Get full access
INTRAORAL AS
AS
Active
Org 928205355
Stålfjæra 4, 3340 Åmot
Wholesale of pharmaceutical and medical goods · NACE 4646
Est. 2021
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
NOK 2,1M
+46% vs 2024
EBITDA margin
7.7%
+367% vs 2024
Equity ratio
1.9%
Financial strength
Net profit 2025
NOK 197K
+136% vs 2024
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2022
0M
0%
2023
0M
0%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
NOK 2,1M
+46%
EBITDA
NOK 162K
+367%
Net profit
NOK 197K
+136%
Total assets
NOK 11,6M
+2%
Equity
NOK 220K
+854%
Employees
0
—
Company information
Legal name
INTRAORAL AS
Org number
928205355
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17. desember 2021
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Kjøp, salg og utleie av eiendom samt det som naturlig står i forbindelse med dette.
Contact
Address
Stålfjæra 4, 3340 Åmot
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Wholesale of pharmaceutical and medical goods
Companies in Modum
All Norway companies
Revenue
NOK millions
0M
1M
1M
2M
2M
0M
2022
0M
2023
1M
2024
2M
2025
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
0M
2025
Income statement
NOK thousands
Item
2022
2023
2024
2025
Revenue
0
0
1 445
2 112
Staff expenses
−0
−0
−35
−314
EBITDA
−13
−9
−61
162
Depreciation & amort.
−0
−0
−0
−0
EBIT
−13
−9
−61
162
Net financials
17
−618
−651
89
Profit before tax
4
−627
−711
251
Tax
−0
−0
−159
54
Net profit
4
−627
−552
197
Balance sheet
NOK thousands
Item
2022
2023
2024
2025
Total assets
11 472
11 298
11 408
11 589
Equity
30
10
23
220
Long-term debt
9 414
9 049
11 327
0
Short-term debt
2 029
2 238
58
215
Total debt
11 442
11 287
11 385
11 369
Financial ratios
5-year trend
EBITDA margin
7.7%
This company
15.8%
Market median
-51% vs market
2022
2025
Equity ratio
1.9%
This company
38.2%
Market median
-95% vs market
2022
2025
Return on equity
89.5%
This company
18.4%
Market median
+386% vs market
2022
2025
Net profit margin
9.3%
This company
8.1%
Market median
+15% vs market
2022
2025
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
2022
2025
Debt / equity
51.64×
This company
0.62×
Market median
-8229% vs market
2022
2025
Annual reports & filings
Annual report 2025
Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2021-11-12 – 2022-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
ZJ
Zoran Jakovljevic
Chief Executive Officer
Chief Executive Officer
2021
Board of directors
Non-executive oversight
Name
Role
Member since
Current (1)
LB
Lise Bjerkerud
Chairman
2021
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Bebanotto As
Company
50%
50%
2022
Tannlege Lise Bjerkerud As
Company
50%
50%
2022
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Tannlege Lise Bjerkerud As
INTRAORAL AS
(this company)
TANNLEGEGÅRDEN AS
Board network connections
Board members of INTRAORAL AS also hold positions in
0
other companies.
Person
Role here
Other companies
Zoran Jakovljevic
Chief Executive Officer
0 companies
Lise Bjerkerud
Chairman
0 companies